Literature DB >> 30642927

In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection.

W J Weiss1, M E Pulse1, P Nguyen1, E J Growcott2.   

Abstract

LYS228 has potent antibacterial activity against carbapenem-resistant strains of Enterobacteriaceae LYS228 was efficacious in neutropenic thigh models established with Klebsiella pneumoniae producing KPC-2 or NDM-1; pretreatment with uranyl nitrate considerably shifted calculated static doses of LYS228. In murine ascending pyelonephritis, LYS228 reduced bacterial burden in kidney, urine, and bladder. The successful treatment of murine infection models established with carbapenem-resistant K. pneumoniae further supports the clinical development of LYS228.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  LYS228; neutropenic thigh model; pyelonephritis

Mesh：

Substances：

Year:  2019        PMID： 30642927      PMCID： PMC6437542          DOI： 10.1128/AAC.02214-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  3 in total

1.  Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Anastasia Bilinskaya; Douglas J Buckheit; Michael Gnoinski; Tomefa E Asempa; David P Nicolau
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

2.  A First-in-Human Study To Assess the Safety and Pharmacokinetics of LYS228, a Novel Intravenous Monobactam Antibiotic in Healthy Volunteers.

Authors:  Megan Osborn; Noah Stachulski; Haiying Sun; Johanne Blais; Vinay Venishetty; Marc Raccuglia; Martin Kankam; Richard Colvin; Florencia Segal
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 3.  Drug development concerning metallo-β-lactamases in gram-negative bacteria.

Authors:  Xiuyun Li; Jing Zhao; Bin Zhang; Xuexia Duan; Jin Jiao; Weiwei Wu; Yuxia Zhou; Hefeng Wang
Journal:  Front Microbiol       Date:  2022-09-15       Impact factor: 6.064
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.